Join the Opdivo Qvantig group to help and get support from people like you.
Opdivo Qvantig News
Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment
WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer. Unfortunately, that hope doesn’t extend to people without health ins...
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
MONDAY, April 21, 2025 — Immunotherapy might help keep lung cancer at bay for months or even years after the treatment has been abandoned due to side effects, a new study says. Immune checkpoint i...
So, Who Benefits From New Cancer Drugs?
THURSDAY, Jan. 16, 2025 – Cutting-edge targeted therapies are pushing back the line between life and death for cancer patients. However, these targeted cancer drugs frequently aren’t benefitting m...
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
FRIDAY, Jan. 3, 2025 – The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
Further information
Related condition support groups
Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma